RxDoctor Payments Data

Tilda Martin, APRN

Nurse Practitioner · Minden, NVNPI 1942676424

Payments from drug & device makers

$1,413in general payments, 2019–2025

Across 91 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$521
  • AbbVie$377
  • AstraZeneca$190
  • Pfizer$100
  • Lilly USA, LLC$58
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$48
  • plus $117 from 4 others

What the payments were for

  • Food & beverage$1,413100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,413 in reported general payments places this provider in the 75th percentile of 933 nurse practitioner providers in Nevada.

See all nurse practitioner providers in Nevada

Medicare billing

Part B allowed, 2024
$1,355
Medicare patients
15
Services billed
17

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$50,084
EliquisApixaban25$33,566
TrulicityDulaglutide27$29,081
FarxigaDapagliflozin Propanediol32$26,092
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,226
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$6,112
JardianceEmpagliflozin11$6,095
Rosuvastatin Calcium72$2,980
Atorvastatin Calcium183$2,958
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate18$2,629
Levothyroxine Sodium212$1,721
Albuterol Sulfate HfaAlbuterol Sulfate61$1,655
SynthroidLevothyroxine Sodium16$1,558
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,078
Losartan Potassium79$967

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$521$50,08439 claims
PfizerEliquis$100$33,56625 claims
Lilly USA, LLCTrulicity$58$29,08127 claims
AstraZenecaFarxiga$190$26,09232 claims
GSKTrelegy Ellipta$16$10,22616 claims
AbbVieSynthroid$377$1,55816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 933 nurse practitioner providers in Nevada.

Other nurse practitioner in Minden

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →